EFFECTOR THERAPEUTICS INC (EFTR) Stock News
NASDAQ:EFTR - Nasdaq - US28202V2079 - Common Stock - Currency: USD
EFTR Latest News, Press Relases and Analysis
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
Explore bankruptcy risk stocks with insights on Chicken Soup for the Soul Entertainment, eFFECTOR Therapeutics, and Delta Apparel.
Mentions: CSSE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!
Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%
EFFECTOR Therapeutics shares are trading lower by 74% during Monday's session. The company announced that it has terminated its employees and will wind down its operations.
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the...
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips eFFECTOR Therapeutics (NASDAQ:EFTR) just reported results for the first quarter...
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
EFTR stock results show that eFFECTOR Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips eFFECTOR Therapeutics (NASDAQ:EFTR) just reported results for the fourth quarte...
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development...
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from...
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development...
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development...
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers on Tuesday as we check out all of the hottest news moving shares this morning!
EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023
EFTR stock results show that eFFECTOR Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in...
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development...
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in...
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Effector Therapeutics announces $15M registered direct offering (NASDAQ:EFTR)
Effector Therapeutics announces a $15 million registered direct offering with a healthcare investor.
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in...
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday morning and we have all the coverage traders need to know about today.